Article

Although there are sound theoretical reasons for the use of botulinum toxin (Btx)
as early as possible in the management of severe childhood muscle spasticity, the
experience with its safety in children younger than 2 years of age is limited and
information about its possible effects on the development and maturation of the
human motor system is still scarce. This study discusses the rationale and the
potential pitfalls of the use of Btx in the first 2 years of the child's life. It
also reviews the currently available evidence on the efficacy and safety of Btx
in this age group. It concludes by suggesting a framework for studies of the
optimal time to start treatment of childhood spasticity with Btx.

Langue : ANGLAIS